ADH-1 has been explored as an antiangiogenic drug in early phase clinical trials in solid tumors and published data indicate a tolerable clinical toxicity profile.23, 24, 25,55 ADH-1 may, therefore, be a candidate for clinical repurposing or a good starting point for a drug-discovery program to meaningfully target the niche in blood cancers. The gene discussed is ADH1A; the disease is hematopoietic and lymphoid system neoplasm.